Company intelligence / Profile preview

PECA Labs

Pittsburgh, Pennsylvania, United Statespecalabs.com ↗

Ownership: Private
Employees: ~21
Development stage: Phase 1

Overview

PECA Labs has achieved over 1,000 human implants of its first device with excellent results. The MASA Valve received Humanitarian Use Device designation from the FDA and began an early feasibility study at five US sites in 2023. exGraft family of vascular grafts has expanded CE Mark approval for use in Europe. Clinical data show improved freedom from re-operation compared to current options for pediatric cardiac surgery

Therapeutic areas: Cardiovascular
Modalities: Device (polymeric heart valves and vascular grafts)
Industry: Implantable Medical Devices

Drug pipeline

5 assets

exGraft

Commercial

Indications: Vascular disease

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on PECA Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PECA Labs.

Explore the full profile